Verastem Inc [VSTM]

Verastem Inc is an emerging biopharmaceutical company dedicated to the creation and commercialization of innovative therapeutic agents for cancer treatment A primary asset in its pipeline is VS6766 a novel dual RAFMEK inhibitor that operates by a clamp mechanism This unique action effectively blocks the kinase activity of MEK and disrupts RAFs ability to phosphorylate MEK The company is actively advancing several clinical trials RAMP 201 is an adaptive twopart multicenter randomized openlabel study designed to assess both the efficacy and safety of VS6766 administered alone or in combination with defactinib Defactinib is an oral small molecule inhibitor of focal adhesion kinase FAK and this trial targets patients with recurrent lowgrade serous ovarian cancer Simultaneously Verastem is conducting RAMP 202 a Phase 2 trial focused on evaluating the safety profile of VS6766 combined with defactinib This particular study enrolls patients with nonsmall cell lung cancer NSCLC that harbors KRAS and BRAF mutations specifically after they have undergone treatment with platinumbased regimens and immune checkpoint inhibitors Verastem has also forged strategic partnerships to support its development efforts It holds license agreements with Chugai Pharmaceutical Co Ltd for the development commercialization and manufacturing rights of products incorporating VS6766 Additionally a similar agreement with Pfizer Inc pertains to the research development production and marketing of Pfizers FAK inhibitors for various human applications including therapeutic diagnostic and prophylactic uses Further expanding its collaborations Verastem has a clinical agreement with Amgen Inc to explore the synergistic potential of VS6766 alongside Amgens KRASG12C inhibitor LUMAKRASTM a combination being investigated in the Phase 12 RAMP 203 trial Founded in 2010 Verastem Inc maintains its corporate headquarters in Needham Massachusetts